Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis

• Peter Nash,
• Luminita Pricop,
• Bruce W Kirkham,
• Alexis Ogdie,
• Effie Pournara,
• Christopher T Ritchlin,
• Matthias Kormaksson,
• Gregory Ligozio

Affiliations

Peter Nash

School of Medicine, Griffith University School of Medicine, Gold Coast, Queensland, Australia

Luminita Pricop

Immunology, Heptatology and Dermatology, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Bruce W Kirkham

Rheumatology, Guy`s and St Thomas` NHS Foundation Trust, London, UK

Alexis Ogdie

Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

Effie Pournara

Immunology, Heptatology and Dermatology, Novartis AG, Basel, Switzerland

Christopher T Ritchlin

Department of Medicine, Allergy/Immunology and Rheumatology (SMD), University of Rochester, Rochester, New York, USA

Matthias Kormaksson

Advanced Exploratory Analytics, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Gregory Ligozio

Immunology, Heptatology and Dermatology, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA